As part of a previously announced reorganization, Pfizer plans to reduce its global headcount by around 2% through voluntary retirements and staff reductions this year and in early 2019. The move will streamline its corporate structure and eliminate some managerial roles and responsibilities.
Read More
|
|
Novartis’ Sandoz, Mylan, Amgen, and Samsung Bioepis have launched in the European Union (EU) biosimilars to AbbVie’s Humira (adalimumab), an anti-inflammatory drug and AbbVie’s top-selling drug with 2017 global sales of $18.43 billion. These companies previously had formed separate agreements with AbbVie to launch their biosimilars of Humira in the EU and US.
Read More
|
|
Novartis has agreed to acquire Endocyte, a biopharmaceutical company developing cancer therapeutics, for approximately $2.1 billion. Endocyte’s lead drug candidate is a-lutetium-based radioligand drug for treating metastatic castration-resistant prostate cancer in Phase III development.
Read More
|
|
Merck & Co. plans to build a second biomanufacturing facility at its site in Carlow, Ireland. It will also expand warehouse and laboratory services at the site.
Read More
|
|
GlaxoSmithKline (GSK) has opened a £54-million ($69-million) active pharmaceutical ingredient (API) production building in Montrose, Scotland for GSK’s Ellipta (fluticasone furoate/vilanterol) respiratory inhalers, a drug to treat chronic obstructive pulmonary disease (COPD) and asthma.
Read More
|
|
Merck KGaA has opened a new EUR 63-million ($72-million) packaging center at its headquarters in Darmstadt, Germany. The new 15,000-square-meter facility will be dedicated to packaging and shipping the company’s current portfolio of medicines to 90-plus countries.
Read More
|
|
Glenmark Pharmaceuticals, a Mumbai, India-headquartered pharmaceutical company, plans to open its first US manufacturing facility in Monroe, North Carolina on October 30. The Monroe facility is designed to manufacture a variety of fixed-dose pharmaceutical formulations, and the company says it expects to make further expansion at the site.
Read More
|
|
The European Medicines Agency (EMA) is evaluating four more “sartan” active pharmaceutical ingredients (APIs) (candesartan, irbesartan, losartan and olmesartan) in hypertension medicines marketed in the EU in addition to its ongoing investigation into impurities found in products containing the API, valsartan.
Read More
|
|
A roundup of expansions and manufacturing updates from suppliers, CDMOs, and CMOs, featuring news from Recipharm, Hovione, Quotient Sciences, Jost Chemical, and Vetter Pharma.
Read More
|
|
|
|
Top Industry News is published and distributed by the
Drug, Chemical & Associated Technologies Association
(DCAT). The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum. For more information, visit
www.dcat.org
.
|
|
|
|
|
|
|
